Key statistics dashboard for Minerva Neurosciences, Inc. (NERV). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system.
Stock Data
| Price | $3.48 |
| Market Cap | $162M |
| Beta | -0.21 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.12 |
| Price / Book | -0.81 |
| P/S | 0.00 |
| P/FCF | -0.01 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 20.14 |
| Quick Ratio | 20.14 |
| Cash Ratio | 6.23 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | -4.33 |
| Cash per share | 1.62 |
| FCF per share | -403.00 |
| Tangible Book Value per share | -4.64 |
| Dividend per share | 0.00 |
Related companies: CLGN · CVKD · ENLV · KLTO · NRSN · NRXS · RLYB
Explore sector: Healthcare · Biotechnology
More sections of NERV: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks